rabbit anti human cd39 polyclonal antibody  (Proteintech)

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Expression Patterns of B7-H3 and CD39 in Gastric Precancerous Lesions and Gastric Cancer Tissues. (A) Representative IHC Expression Patterns of B7-H3 and CD39 Across Different Pathological Stages (CSG, CAG, LGIN, HGIN, and GC). (B) Quantitative Analysis of Positive Expression Areas of CD39. (C) Quantitative Analysis of Positive Expression Areas of B7-H3. (D) Representative Multiplex IHC Expression Patterns of B7-H3 and CD39 Across Different Pathological Stages (CSG, CAG, LGIN, HGIN, and GC). (E) Quantitative Analysis of Multiplex IHC Expression of B7-H3 and CD39. (F) Representative Co-Localization Expression of B7-H3 and CD39 in GC. IHC Scale Bars: 50 µm; mIHC Scale Bars: 100 µm.

Article Snippet: The following primary antibodies were used according to the manufacturer's instructions: mouse anti-human B7-H3 monoclonal antibody, 1/200 dilution (Cat No: 66 481-1-Ig, Proteintech, China), rabbit anti-human CD39 polyclonal antibody, 1/1000 dilution (Cat No: 14211-1-AP, Proteintech, China) and mouse anti-human CD8 monoclonal antibody, 1/10 000 dilution (Cat No: 66868-1-Ig, Proteintech, China).

Techniques: Expressing, Multiplex Assay

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Co-Localization of B7-H3 and CD39 in Gastric Cancer Cells Indicates Poor Prognosis. (A, B) Representative Immunohistochemical Images Showing Low and High Expression of B7-H3 (A) and CD39 (B) in Gastric Cancer (GC) Specimens. (C) Correlation Analysis of B7-H3 and CD39 Expression. (F, G, H, I) Kaplan-Meier Survival Curves for Overall Survival of GC Patients Based on the Expression Status of B7-H3 (F), CD39 (G), Dual High Expression of B7-H3 and CD39 (H), and Co-Localized Expression Status of B7-H3-CD39 (I). Scale Bars: 100 µm.

Article Snippet: The following primary antibodies were used according to the manufacturer's instructions: mouse anti-human B7-H3 monoclonal antibody, 1/200 dilution (Cat No: 66 481-1-Ig, Proteintech, China), rabbit anti-human CD39 polyclonal antibody, 1/1000 dilution (Cat No: 14211-1-AP, Proteintech, China) and mouse anti-human CD8 monoclonal antibody, 1/10 000 dilution (Cat No: 66868-1-Ig, Proteintech, China).

Techniques: Immunohistochemical staining, Expressing

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Absence of Correlation Between Co-localization of B7-H3 and CD39 Expression and CD8 + T Cell Infiltration in Gastric Cancer. (A, B) Representative Immunohistochemical Images Showing the Expression of B7-H3 with CD8 (A) or CD39 with CD8 (B) in the Same Patient. (C) Correlation Between B7-H3 Expression and CD8 Expression, and Between CD39 Expression and CD8 Expression. (D, E) Representative Multiplex Immunohistochemistry Images of B7-H3, CD39, and CD8 (D), and Correlation Analysis Between the Co-Localization Expression Score of B7-H3 and CD39 and the Extent of CD8 Infiltration (E). (F, G) Representative Multiplex Immunohistochemistry Images of CD39 and CD8, with Arrows Indicating CD39 + CD8 + T Cells (F), and the Proportion of CD39 + CD8 + T Cells within the CD8 + T Cell Population (G). Scale Bars: 100 µm.

Article Snippet: The following primary antibodies were used according to the manufacturer's instructions: mouse anti-human B7-H3 monoclonal antibody, 1/200 dilution (Cat No: 66 481-1-Ig, Proteintech, China), rabbit anti-human CD39 polyclonal antibody, 1/1000 dilution (Cat No: 14211-1-AP, Proteintech, China) and mouse anti-human CD8 monoclonal antibody, 1/10 000 dilution (Cat No: 66868-1-Ig, Proteintech, China).

Techniques: Expressing, Immunohistochemical staining, Multiplex Assay, Immunohistochemistry

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Kaplan-Meier Survival Curves for Gastric Cancer Patients Based on Specific Expression Statuses and Immune Cell Infiltration Levels. (A, B, C, D) Kaplan-Meier Survival Curves for GC Patients Stratified by B7-H3 High CD8 Low (A) Expression Status 、 CD39 High CD8 Low (B) Expression Status 、 B7-H3-CD39 Both high CD8 Low Expression Status (C) and B7-H3-CD39 Co-localization CD8 low Expression Status (D). (E, F) Kaplan-Meier Survival Curves for GC Patients Based on CD8 + T Cell Infiltration Levels (E) and CD39 + CD8 + T Cell Infiltration Status (F).

Article Snippet: The following primary antibodies were used according to the manufacturer's instructions: mouse anti-human B7-H3 monoclonal antibody, 1/200 dilution (Cat No: 66 481-1-Ig, Proteintech, China), rabbit anti-human CD39 polyclonal antibody, 1/1000 dilution (Cat No: 14211-1-AP, Proteintech, China) and mouse anti-human CD8 monoclonal antibody, 1/10 000 dilution (Cat No: 66868-1-Ig, Proteintech, China).

Techniques: Expressing

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet: Increased ENTPD1 levels in lung, liver, spleen, and PBMCs from severe COVID-19 patients (A) Heatmaps representing the Treg gene set in lung, liver, and spleen of COVID-19 patients, compared with controls. Upregulated and downregulated genes are shown in red and blue. (B) Box plots showing the median ENTPD1 levels in biopsies from autoptic lung, heart, liver, kidney and spleen of COVID-19 patients (lung n = 5, liver n = 5, spleen n = 3) and controls (n = 2 for all organs). Results were obtained by NanoString. ∗p ≤ 0.05; ∗∗p ≤ 0.01 using two-sided unpaired t test. Samples were run in triplicate and experiments performed independently three times. (C) Expression of CD39 was tested in paraffin embedded sections obtained from biopsies of autoptic COVID-19 and control lung, heart, liver, kidney and spleen. Immunohistochemistry staining is shown from one COVID-19 patient and one control. Arrows indicate positively stained cells (magnification 20 x, scale bar 100 μM). A representative of three independent staining is shown. (D) ENTPD1 mRNA levels in PBMCs were determined by qPCR in moderate (n = 20), severe (n = 15), convalescent (n = 6) COVID-19 cases and in healthy controls (n = 6). Mean ± SEM is shown. ∗p ≤ 0.05, ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey’s multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. (E–H) Correlation between ENTPD1 mRNA levels and (E) D-Dimer, (F) prothrombin time (PT), length of stay in (G) hospital, and (H) intensive care unit (ICU) in moderate and severe patients. Coefficients associated with significant (p ≤ 0.05) correlations are indicated. See also Figure S5 .

Article Snippet: Sections were subsequently incubated overnight at 4°C with rabbit polyclonal anti-human CD39 (cat. # HPA014067, Sigma Aldrich) at 1/100 ( ).

Techniques: Expressing, Immunohistochemistry, Staining

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet: ENTPD1 is aberrantly regulated in severe COVID-19 patients (A) Volcano plot showing down- and upregulated genes within the high ENTPD1 expressing group. High and low ENTPD1 expression was defined based on the median value (median ENTPD1 levels: 9.9, range: 9.43–10.77 obtained after pooling the ENTPD1 gene expression levels of severe and convalescent cases. nCounter CAR-T genes were then subdivided based on ENTPD1 levels and subsequently associated with high or low ENTPD1 expression. X and Y axes correspond to fold change and p value respectively. Downregulated and upregulated genes are shown in blue and red. The most significantly downregulated and upregulated genes are indicated. (B) Gene set enrichment analysis (GSEA) showing the gene pathways associated with high and low ENTPD1 expression levels (p value < 0.05 and false discovery rate q value < 0.05). High and low ENTPD1 expression was defined based on the median value obtained after pooling the ENTPD1 gene expression levels of severe and convalescent cases. nCounter CAR-T genes were then subdivided based on ENTPD1 levels and associated with high or low ENTPD1 expression. Lines represent individual gene sets. Upregulated genes are located on the left, while downregulated genes are located on the right of the plot. (C) PPI network between ENTPD1/CD39 and other protein-coding genes included in the nCounter CAR-T characterization panel was derived by STRING (threshold value of median confidence of 0.4). (D–F) Box plots showing the median (D) STAT-3 , (E) HIF-1α , and (F) AHR mRNA levels in PBMCs from moderate (n = 6), severe (n = 6) and convalescent (n = 6) COVID-19 patients and healthy controls (n = 6). Data were obtained by NanoString analysis. ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey's multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. (G) Levels of ENTPD1-AS RNA were tested by qPCR in moderate (n = 20), severe (n = 15), convalescent (n = 6) COVID-19 cases and in healthy controls (n = 6). Mean ± SEM ENTPD1-AS RNA is shown. ∗p ≤ 0.05, ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey’s multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. See also and .

Article Snippet: Sections were subsequently incubated overnight at 4°C with rabbit polyclonal anti-human CD39 (cat. # HPA014067, Sigma Aldrich) at 1/100 ( ).

Techniques: Expressing, Derivative Assay

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet:

Article Snippet: Sections were subsequently incubated overnight at 4°C with rabbit polyclonal anti-human CD39 (cat. # HPA014067, Sigma Aldrich) at 1/100 ( ).

Techniques: Plasmid Preparation, Software

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet: Increased ENTPD1 levels in lung, liver, spleen, and PBMCs from severe COVID-19 patients (A) Heatmaps representing the Treg gene set in lung, liver, and spleen of COVID-19 patients, compared with controls. Upregulated and downregulated genes are shown in red and blue. (B) Box plots showing the median ENTPD1 levels in biopsies from autoptic lung, heart, liver, kidney and spleen of COVID-19 patients (lung n = 5, liver n = 5, spleen n = 3) and controls (n = 2 for all organs). Results were obtained by NanoString. ∗p ≤ 0.05; ∗∗p ≤ 0.01 using two-sided unpaired t test. Samples were run in triplicate and experiments performed independently three times. (C) Expression of CD39 was tested in paraffin embedded sections obtained from biopsies of autoptic COVID-19 and control lung, heart, liver, kidney and spleen. Immunohistochemistry staining is shown from one COVID-19 patient and one control. Arrows indicate positively stained cells (magnification 20 x, scale bar 100 μM). A representative of three independent staining is shown. (D) ENTPD1 mRNA levels in PBMCs were determined by qPCR in moderate (n = 20), severe (n = 15), convalescent (n = 6) COVID-19 cases and in healthy controls (n = 6). Mean ± SEM is shown. ∗p ≤ 0.05, ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey’s multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. (E–H) Correlation between ENTPD1 mRNA levels and (E) D-Dimer, (F) prothrombin time (PT), length of stay in (G) hospital, and (H) intensive care unit (ICU) in moderate and severe patients. Coefficients associated with significant (p ≤ 0.05) correlations are indicated. See also Figure S5 .

Article Snippet: Rabbit polyclonal anti-human CD39 , Sigma Aldrich , Cat. # HPA014067; RRID: AB_1848178.

Techniques: Expressing, Immunohistochemistry, Staining

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet: ENTPD1 is aberrantly regulated in severe COVID-19 patients (A) Volcano plot showing down- and upregulated genes within the high ENTPD1 expressing group. High and low ENTPD1 expression was defined based on the median value (median ENTPD1 levels: 9.9, range: 9.43–10.77 obtained after pooling the ENTPD1 gene expression levels of severe and convalescent cases. nCounter CAR-T genes were then subdivided based on ENTPD1 levels and subsequently associated with high or low ENTPD1 expression. X and Y axes correspond to fold change and p value respectively. Downregulated and upregulated genes are shown in blue and red. The most significantly downregulated and upregulated genes are indicated. (B) Gene set enrichment analysis (GSEA) showing the gene pathways associated with high and low ENTPD1 expression levels (p value < 0.05 and false discovery rate q value < 0.05). High and low ENTPD1 expression was defined based on the median value obtained after pooling the ENTPD1 gene expression levels of severe and convalescent cases. nCounter CAR-T genes were then subdivided based on ENTPD1 levels and associated with high or low ENTPD1 expression. Lines represent individual gene sets. Upregulated genes are located on the left, while downregulated genes are located on the right of the plot. (C) PPI network between ENTPD1/CD39 and other protein-coding genes included in the nCounter CAR-T characterization panel was derived by STRING (threshold value of median confidence of 0.4). (D–F) Box plots showing the median (D) STAT-3 , (E) HIF-1α , and (F) AHR mRNA levels in PBMCs from moderate (n = 6), severe (n = 6) and convalescent (n = 6) COVID-19 patients and healthy controls (n = 6). Data were obtained by NanoString analysis. ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey's multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. (G) Levels of ENTPD1-AS RNA were tested by qPCR in moderate (n = 20), severe (n = 15), convalescent (n = 6) COVID-19 cases and in healthy controls (n = 6). Mean ± SEM ENTPD1-AS RNA is shown. ∗p ≤ 0.05, ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey’s multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. See also and .

Article Snippet: Rabbit polyclonal anti-human CD39 , Sigma Aldrich , Cat. # HPA014067; RRID: AB_1848178.

Techniques: Expressing, Derivative Assay

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet:

Article Snippet: Rabbit polyclonal anti-human CD39 , Sigma Aldrich , Cat. # HPA014067; RRID: AB_1848178.

Techniques: Plasmid Preparation, Software